Factor VIII Inhibitors in Hemophilia A: Rationale and Latest Evidence

Overview

Journal Ther Adv Hematol

Specialty Hematology

Date 2013 Apr 24

PMID 23610614

Citations 73

Authors

Char Witmer

Guy Young

Affiliations

Soon will be listed here.

Abstract

Factor VIII (FVIII) replacement therapy is the foundation of treatment in hemophilia A and is effective unless a patient develops an alloantibody (inhibitor) against exogenous FVIII. Inhibitor development is currently the most significant treatment complication seen in patients with hemophilia and is associated with considerable morbidity and a decreased quality of life. The development of an inhibitor is the result of a complex interaction between a patient's immune system and genetic and environmental risk factors. The mainstay of treatment is the eradication of the inhibitor through immune tolerance. This review summarizes the current evidence regarding inhibitor risk factors, eradication, and hemostatic bypassing agents.

Citing Articles

Prevalence of Hemophilia and Clinicodemographic Characteristics of Hemophilic Patients Aged ≤ 18 Years in Thi-Qar, Iraq.

Abood G, Dehiol R, Mones H Glob Pediatr Health. 2024; 11:2333794X241280119.

PMID: 39281354 PMC: 11401012. DOI: 10.1177/2333794X241280119.

The Evolution of Hemophilia Therapeutics: An Illustrated Review.

Espanol M, Mistretta J, Tarantino M, Roberts J Res Pract Thromb Haemost. 2024; 8(3):102308.

PMID: 38883215 PMC: 11180375. DOI: 10.1016/j.rpth.2023.102308.

Emicizumab as a Promising Form of Therapy for Type A Hemophilia - A Review of Current Knowledge from Clinical Trials.

Grabowska K, Grzelak M, Zhao L, Pluciennik E, Pasieka Z, Kciuk M Curr Protein Pept Sci. 2024; 25(9):719-737.

PMID: 38797909 DOI: 10.2174/0113892037294674240509094418.

Emicizumab prophylaxis in people with hemophilia A and inhibitors: a systematic review and meta-analysis.

Prudente T, Camelo R, Guimaraes R, Roberti M Sao Paulo Med J. 2024; 142(5):e2023102.

PMID: 38747872 PMC: 11087007. DOI: 10.1590/1516-3180.2023.0102.R1.20022024.

Therapeutic proteins: developments, progress, challenges, and future perspectives.

Kumar V, Barwal A, Sharma N, Mir D, Kumar P, Kumar V 3 Biotech. 2024; 14(4):112.

PMID: 38510462 PMC: 10948735. DOI: 10.1007/s13205-024-03958-z.

References

Aledort L, DiMichele D . Inhibitors occur more frequently in African-American and Latino haemophiliacs. Haemophilia. 1999; 4(1):68. DOI: 10.1046/j.1365-2516.1998.0146c.x. View

Scandella D, Mattingly M, de Graaf S, Fulcher C . Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood. 1989; 74(5):1618-26. View

Mauser-Bunschoten E, den Uijl I, Schutgens R, Roosendaal G, Fischer K . Risk of inhibitor development in mild haemophilia A increases with age. Haemophilia. 2011; 18(2):263-7. DOI: 10.1111/j.1365-2516.2011.02629.x. View

Hay C, Ludlam C, Colvin B, Hill F, Preston F, Wasseem N . Factor VIII inhibitors in mild and moderate-severity haemophilia A. UK Haemophilia Centre Directors Organisation. Thromb Haemost. 1998; 79(4):762-6. View

Su R, Epp A, Latchman Y, Bolgiano D, Pipe S, Josephson N . Suppression of FVIII inhibitor formation in hemophilic mice by delivery of transgene modified apoptotic fibroblasts. Mol Ther. 2009; 18(1):214-22. PMC: 2839230. DOI: 10.1038/mt.2009.209. View

Mariani G, Scheibel E, Nogao T, Kasper C, Ewing N, Mauser-Bunschoten E . Immunetolerance as treatment of alloantibodies to factor VIII in hemophilia. The International Registry of Immunetolerance Protocols. Semin Hematol. 1994; 31(2 Suppl 4):62-4. View

Oldenburg J, Schroder J, Brackmann H, Muller-Reible C, Schwaab R, Tuddenham E . Environmental and genetic factors influencing inhibitor development. Semin Hematol. 2004; 41(1 Suppl 1):82-8. DOI: 10.1053/j.seminhematol.2003.11.016. View

Mannucci P, Gringeri A, Peyvandi F, Santagostino E . Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia. 2008; 13 Suppl 5:65-8. DOI: 10.1111/j.1365-2516.2007.01580.x. View

Kempton C, Soucie J, Miller C, Hooper C, Escobar M, Cohen A . In non-severe hemophilia A the risk of inhibitor after intensive factor treatment is greater in older patients: a case-control study. J Thromb Haemost. 2010; 8(10):2224-31. PMC: 3612936. DOI: 10.1111/j.1538-7836.2010.04013.x. View

10.

Berntorp E, Astermark J, Carlborg E . Immune tolerance induction and the treatment of hemophilia. Malmö protocol update. Haematologica. 2001; 85(10 Suppl):48-50; discussion 50-1. View

11.

Eckhardt C, Kamphuisen P, Fijnvandraat K . Inhibitors of factor VIII in hemophilia. N Engl J Med. 2009; 361(3):309. View

12.

Saint-Remy J, Lacroix-Desmazes S, Oldenburg J . Inhibitors in haemophilia: pathophysiology. Haemophilia. 2004; 10 Suppl 4:146-51. DOI: 10.1111/j.1365-2516.2004.01009.x. View

13.

Kurczynski E, Penner J . Activated prothrombin concentrate for patients with factor VIII inhibitors. N Engl J Med. 1974; 291(4):164-7. DOI: 10.1056/NEJM197407252910402. View

14.

Ragni M, Ojeifo O, Feng J, Yan J, Hill K, Sommer S . Risk factors for inhibitor formation in haemophilia: a prevalent case-control study. Haemophilia. 2009; 15(5):1074-82. PMC: 2734871. DOI: 10.1111/j.1365-2516.2009.02058.x. View

15.

Nilsson I, Berntorp E, ZETTERVALL O . Induction of immune tolerance in patients with hemophilia and antibodies to factor VIII by combined treatment with intravenous IgG, cyclophosphamide, and factor VIII. N Engl J Med. 1988; 318(15):947-50. DOI: 10.1056/NEJM198804143181503. View

16.

Hoots W, Ebbesen L, Konkle B, Auerswald G, Roberts H, Weatherall J . Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia. 2008; 14(3):466-75. DOI: 10.1111/j.1365-2516.2008.01654.x. View

17.

Manco-Johnson M, Abshire T, Shapiro A, Riske B, Hacker M, Kilcoyne R . Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007; 357(6):535-44. DOI: 10.1056/NEJMoa067659. View

18.

Haya S, Lopez M, Aznar J, Batlle J . Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry. Haemophilia. 2001; 7(2):154-9. DOI: 10.1046/j.1365-2516.2001.00469.x. View

19.

Schneiderman J, Nugent D, Young G . Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors. Haemophilia. 2004; 10(4):347-51. DOI: 10.1111/j.1365-2516.2004.00912.x. View

20.

Astermark J, Berntorp E, White G, Kroner B . The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia. 2001; 7(3):267-72. DOI: 10.1046/j.1365-2516.2001.00510.x. View